Yuri Punj

[Yuri Punj @ypunj]

@leevalueroach The stock has held extraordinarily well despite the selling pressure. Once it subsides, the stock should accelerate higher.

[Yuri Punj @ypunj]

@Mike10947310 Current thoughts on $FNCHQ

[Yuri Punj @ypunj]

@WallStWary @terribadrob Any reason for selloff?

[Yuri Punj @ypunj]

@suresh_sivap Any response from them

[Yuri Punj @ypunj]

@BoringBiz_ Vedanta recommends something before any major life decision:

"At the end of my life, looking back — which choice will feel like the real me?"

The path forward, as Vedanta sees it, is not escape. It is clarity. Let him ask: what would he choose if nobody were watching?

[Yuri Punj @ypunj]

@SSI_invest Under 2x EBITDA...tremendously undervalued bid

[Yuri Punj @ypunj]

@TrentBlair19 Hoping the 20 day go shop period results in a higher bid. Tremendously undervalued bid.

[Yuri Punj @ypunj]

@everyonehatesp1 $PSRHF - play on helium shortage

[Yuri Punj @ypunj]

@ZZZBBB12345 @BATMongoose Would love to buy more, but fully sized at higher levels. 3-4x upside from here.

[Yuri Punj @ypunj]

@Mike10947310 In the meantime, we get paid to wait as interest on the judgement accrues at the Federal Reserve discount rate plus 5%.

[Yuri Punj @ypunj]

@Steven_Kiel @CFAs4CFPs Does the Chapter 11 get them out of the lease obligation?

[Yuri Punj @ypunj]

@BATMongoose @Mike10947310 Shouldn't impact the trial outcome and that is the true driver of value here.

[Yuri Punj @ypunj]

@Mike10947310 Can't find anything either...trying to figure out if get me out at all costs selloff warrants buying here

[Yuri Punj @ypunj]

@Steven_Kiel What's happening with $FNCH. You guys hearing anything?

[Julian Klymochko @JulianKlymochko]

If you read one thing on private credit today, make it Sixth Street's investor letter. The highlights:

“Crises don’t happen because of credit issues, they happen because of liquidity issues.

"If you believe in efficient markets, public BDCs trading at significant discounts versus similar private counterparts is an arbitrage that will resolve over time. Capital will be reallocated, and the public BDC sector should benefit as the liquidity-taking abates and discounts normalize."

"The weighted average price-to-book (“P/B”) ratio of these sixteen public BDCs is 0.83x, while equity in their non-traded BDCs can be redeemed at 1.00x P/B."

"The rebalancing of the ecosystem will take time to fully materialize, but it should ultimately result in the widening of new origination spreads and a healthy recalibration of the supply-demand dynamic for private capital."

"As we witnessed during the redemption cycle that impacted non-traded REITs in 2022, flows are typically correlated in the sense that in periods of significant redemptions, inflows tend to decline significantly. That is what we are now seeing in the non-traded BDC market."

"We believe it is worth reminding ourselves that the current dislocation across the BDC sector is taking place in the context of a relatively constructive economic backdrop. Consumer balance sheets remain healthy, corporate earnings growth has been solid, and unemployment is still near historic lows despite the most recent jobs report. The economy broadly speaking is in decent shape."

"We believe the current AI fear in the market is largely an equity valuation problem. While equity owners may be the first to absorb downward pressure as multiples re-rate, TSLX remains positioned at the top of the capital structure... Despite our enthusiasm, we see excess hype (and inversely, excess fear) in the market discourse. Both sides of this coin lack nuance, brushing very different businesses with a broad stroke and conflating credit risk with equity valuation problems."

[Yuri Punj @ypunj]

@given2tweet This whole thing has been a joke by them...i will take the loss and move on. Don't trust anything they say

[Yuri Punj @ypunj]

@LionelHutz_Esq Thoughts on the $ABUS settlement with PFE optionality

[Yuri Punj @ypunj]

@ACapitalLP $LQDA - market prices it like a litigation-constrained biotech, but a clear commercial path for YUTREPIA against United Therapeutics could unlock rapid revenue scaling and multiple expansion.

[Yuri Punj @ypunj]

@MaartenDik What are your thoughts on the stock after the conference call?